Outlook Therapeutics OTLKW 深 沪
已收盘 02-16 16:00:00 美东时间
0.03
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.03
- 总市值 8.75万
- 52周最高 1.27
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.01
- 委 比 0.00%
- 总股本 291.70万
- 历史最高 3.49
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.01
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Outlook Therapeutics reported a net loss of $62.4M ($1.79 per share) for fiscal year 2025, with $1.4M in revenue from initial sales of LYTENAVA™ in Germany and the UK. The company saw reduced R&D expenses and increased SG&A costs due to the product launch. Cash reserves totaled $8.1M as of September 30, 2025. The FDA PDUFA date for ONS-5010 is December 31, 2025, and the company is expanding commercially in Europe and preparing for potential U.S. ...
12-19 13:05
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Outlook Therapeutics' CEO, Bob Jahr, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:00 AM ET. A live webcast of the chat will be available on the company's website, with a replay archived for 90 days. Management will also host one-on-one meetings with investors. Outlook Therapeutics focuses on developing LYTENAVA™ for treating retinal diseases, which is the first approved opht...
11-24 14:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 205.0% to $27.05...
11-14 01:06
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics announced that the FDA has accepted the resubmission of the BLA for ONS-5010 (bevacizumab-vikg) for wet AMD treatment. The PDUFA goal date is set for December 31, 2025. If approved, ONS-5010 will be marketed as LYTENAVA™, the first FDA-approved ophthalmic bevacizumab formulation in the U.S. The company addressed feedback from the August 2025 CRL and expects a 60-day review period. LYTENAVA™ is already authorized in Europe and...
11-13 13:30
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Outlook Therapeutics has resubmitted its BLA to the FDA for ONS-5010, an ophthalmic formulation of bevacizumab aimed at treating wet AMD, following feedback from a September 2025 Type A meeting. The company believes this action addresses the issues highlighted in the August 2025 CRL. CEO Bob Jahr emphasized the importance of this step in achieving U.S. approval and highlighted ongoing European commercialization efforts. ONS-5010, branded as LYTEN...
11-03 13:35
HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $1 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $1 price target.
09-30 19:41
Outlook Therapeutics Completes FDA Meeting on ONS-5010
Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On September 29...
09-30 05:33
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $8
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $21 to $8.
09-22 17:30
Outlook Therapeutics CCO Jeff Evanson Steps Down
Outlook Therapeutics ( ($OTLK) ) has provided an announcement. On September 5, ...
09-06 05:33
FDA Issues Complete Response Letter to Outlook Therapeutics
Outlook Therapeutics ( ($OTLK) ) has issued an update. On August 28, 2025, Outl...
09-03 05:32
